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Abstract 
Preformed and de novo donor-specific antibodies (DSAs) are established 
major risk factors for antibody-mediated rejection (ABMR) in solid organ 
transplantation. While current immunosuppressants are effective in controlling 
acute T cell-mediated rejection, ABMR prevention and reversal remain major 
medical challenges. Therefore, effective anti-ABMR therapy is strongly needed to 
improve overall graft survival and patient quality of life. Cathepsin S (Cat S) is a 
protease that is essential for antigen peptide generation and loading of 
lysosomal/endosomal major histocompatibility complex (MHC) class II molecules 
that are subsequently presented to CD4+ T cells. Cat S deficiency leads to the 
inhibition of germinal center development and suppression of humoral immune 
response without major developmental abnormalities in T and B lymphocytes. 
Many studies on Cat S inhibitors or Cat S null mice suggest that this protease plays 
a role in preventing autoimmunity by impairing autoantigen presentation to 
autoreactive T cells and reducing immunoglobulin G (IgG) autoantibody 
production. Indeed, Cat S inhibitors are currently under development as therapeutic 
agents for several autoimmune diseases. While the potential benefits of Cat S 
inhibitors for organ transplantation have not been reported, various benefits are 
likely given that Cat S inhibition may prevent both cellular and humoral responses 
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involved in graft rejection. 
Here, I investigated the pharmacological profile of novel Cat S inhibitors, 
AS2761325 and AS2863995, and explored their preventive potential on DSA 
production and acute rejection in a mouse cardiac transplantation model. Cat S 
inhibitors potently inhibited upregulation of allogeneic antigen peptide loading 
MHC class II expression on the surface of splenic B cells and suppressed 
ovalbumin (OVA)-induced T cell-dependent antibody production in mice. In a 
mouse cardiac transplantation model, oral administration of AS2761325 
monotherapy inhibited DSA production even without affecting graft survival. This 
profile was unique compared to conventional immunosuppressants, tacrolimus and 
mycophenolate mofetil (MMF). When combined with a suboptimal dose of 
tacrolimus, AS2761325 significantly prolonged graft survival. The more potent Cat 
S inhibitor AS2863995 also prolonged graft survival and almost completely 
suppressed DSA production at a lower dose than that of AS2761325, potentially 
due to its higher Cat S inhibition potency. Furthermore, AS2863995 showed a 
comparable preventive effect on acute rejection and a more preferential inhibitory 
effect on DSA production compared to 50 mg/kg of MMF, which is maximum 
tolerable dosage of MMF in mice. These data indicate that Cat S inhibitors are 
effective for graft survival prolongation, and preferentially suppress DSA 
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production in organ transplantation. 
An inhibitory effect on DSA production was also observed in recipients 
treated with high doses of tacrolimus and MMF. However, current maintenance 
immunotherapies cannot overcome the issues associated with ABMR. In fact, the 
doses of both tacrolimus and MMF are limited due to side effects such as increased 
susceptibility to infection that restricts their maximum efficacy, and overall suggest 
the need to balance the benefit of DSA suppression and the risk of side effects. 
Immunosuppressants that predominantly inhibit DSA production may do so 
without increasing safety concerns compared to nonselective immunosuppressants. 
Conventional immunosuppressants that act on various types of immune cells, 
including CD4+ and CD8+ T cells in the direct allorecognition pathway, are 
preferable at the early stages of transplantation due to the lifespan of donor-derived 
antigen presenting cells. Effective suppression of DSA production by Cat S 
inhibitors due to their selective inhibition of the indirect pathway suggests that they 
have a good profile as ABMR inhibitors in the maintenance phase, when indirect 
allorecognition is dominant. 
In conclusion, I revealed that Cat S inhibitors may be promising candidate 
ABMR prophylaxis drugs. The different profiles of Cat S inhibitors and calcineurin 
inhibitors may make better combination immunosuppressive maintenance therapy 
4 
 
to control both cell-mediated and antibody-mediated rejection. 
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Abbreviations 
ABMR  antibody-mediated rejection 
APCs   antigen presenting cells 
Cat S  cathepsin S 
CLIP   class II associated invariant chain peptide 
CNIs   calcineurin inhibitors 
DMSO  dimethyl sulfoxide 
DSA   donor-specific antibodies 
FITC   fluorescein isothiocyanate 
HCT   hematocrit  
HGB   hemoglobin  
HLA   human leukocyte antigen 
Ig  immunoglobulin 
LPS   lipopolysaccharide 
MC   methylcellulose  
MHC   major histocompatibility complex 
MMF   mycofenolate mofetil 
MST  median survival time 
OVA   ovalbumin  
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PAR   protease-activated receptor  
PE   phycoerythrin 
PG   propylene glycol 
RBC   red blood cells 
RET   reticulocyte  
SDF  solid dispersion formulation 
S.E.M  standard error of the mean 
TCMR   T cell-mediated rejection 
TCR  T cell receptor 
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General Introduction 
Organ transplantation is a lifesaving treatment for patients with chronic organ 
failure. According to the Organ Procurement Agency of Michigan, one donor can 
save 8 lives with organs and can improve 75 lives with tissues. In fact, kidney 
transplantations can improve lives for an average of 12 -15 years, and 70 % of liver 
and heart transplant patients can survive more than 5 years (Gift of Life Michigan). 
However, we all have immune system to protect ourselves from non-self-invasion, 
and the transplanted donor allografts are rejected by recipient’s immune system. 
Therefore, its success has risen following advances in the development of various 
immunosuppressants. 
The history of transplantation medicine began with the success of kidney 
transplantation among identical twins by Murray et al. in 1954. At that time, 
rejection reactions in combinations other than identical twins could not of course 
be controlled, and outcomes were very poor (Murray and Harrison, 1963). The 
emergence of calcineurin inhibitors (CNIs) has overcome this situation. 
Cyclosporine, which appeared in the 1980s, and tacrolimus, which appeared in the 
1990s, dramatically improved the results of graft survival, and thereafter induction 
therapy and maintenance therapy targeting T cells have been actively developed.  
Immune system is an important mechanism in host defense against pathogens, 
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and all immunosuppressants are faced with inducing a high risk of infection. The 
doses of immunosuppressants are limited due to their side effects, which restricts 
their maximum efficacy. Therefore, the multidrug combination therapy is the 
standard of care in transplantation therapy, and the calcineurin inhibitor tacrolimus, 
the antimetabolite MMF, and steroids are most commonly used in the maintenance 
phase. In addition to these drugs, induction therapy targeting T cells such as anti-
interleukin-2 receptor antibody make it possible for the acute phase T cell-mediated 
rejection (TCMR) to be very well controlled (Meier-Kriesche et al., 2006). While 
current immunosuppressants are usually effective for controlling acute TCMR, 
they have not been successful for ABMR (Valenzuela and Reed, 2017). Inadequate 
control of ABMR causes a decline in long-term graft survival (Terasaki and Cai, 
2008; Wiebe et al., 2015). Therefore, effective anti-ABMR therapies are strongly 
needed to improve overall graft survival in organ transplant therapy.  
Donor human leukocyte antigen (HLA)-specific antibodies (DSA) are triggers 
for several immunological reactions: complement activation, endothelial cell injury, 
and infiltration of innate immune cells in the transplanted organ (Collins et al., 
1999; Fishbein and Fishbein, 2012; Li et al., 2011). These immunological reactions 
are also integral to acute or chronic ABMR. For patients showing high levels of 
anti-HLA antibodies prior to transplantation (caused by pre-transplant sensitization 
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to non-donor HLA such as in pregnancy, transfusion, and tissue grafting), induction 
therapies combining intravenous immunoglobulin, plasmapheresis and anti-CD20 
immunotherapy can reduce the risk of ABMR by temporally reducing circulating 
DSA levels (Jordan et al., 2004; Vo et al., 2008). This suggests that controlling DSA 
levels may be a promising approach for treating or preventing ABMR. However, 
such induction therapy is generally accompanied by the risk of side effects such as 
impaired broad-range humoral immunity, and cannot be used continuously in the 
maintenance phase. Furthermore, newly formed de novo DSA directed against 
donor HLA is known to strongly induce graft injury (Loupy et al., 2013; O'Leary 
et al., 2016). Risk factors for de novo DSA formation include pre-transplant 
sensitization to non-donor HLA, as well as acute cell-mediated rejection in the first 
year after transplantation and donor-recipient incompatibility of HLA-DQ. More 
than half of patients on the US renal transplant waitlist exhibit these high-risk 
factors for de novo DSA expression (Valenzuela and Reed, 2017). I therefore 
considered that novel therapies that can effectively prevent de novo or recurrent 
DSA production in the maintenance phase would be promising for ABMR 
suppression.  
Cat S plays a key role in MHC class II antigen presentation by processing 
invariant chain on MHC class II molecules and promoting antigen peptide loading 
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onto them. Cat S deficiency leads to the inhibition of germinal center development 
and suppression of humoral immune response without major developmental 
abnormalities in T and B lymphocytes (Nakagawa et al., 1999; Shi et al., 1999). 
Lack of Cat S or pharmacological Cat S inhibition leads to suppression of humoral 
autoimmunity in many animal models (Irie et al., 2008; Saegusa et al., 2002; Tato 
et al., 2017). Inhibition of Cat S is expected to diminish alloantibody production 
and improve graft survival and may therefore be a promising ABMR prophylactic 
maintenance therapy. However, there is no report on the study of Cat S inhibitors 
in solid organ transplantation.  
There are two allorecognition pathways in transplantation (Fig.1). One is the 
direct allorecognition pathway, in which recipient CD4+ T cells are activated by 
donor APCs, and the other is the indirect allorecognition pathway, in which 
recipient CD4+ T cells are activated by donor-antigen presenting recipient APCs 
(Lechler et al., 2005). DSA production causing ABMR is known to be critically 
dependent on CD4+ T cells (Lovegrove et al., 2001), especially activated via the 
indirect allorecognition pathway (Bishop et al., 1994; Conlon et al., 2012; Irie, 
2013; Lechler et al., 2005). Since Cat S is most likely involved in the indirect 
allorecognition pathway, so-called DSA production pathway, Cat S inhibitors were 
considered to have a good profile as ABMR prophylactic drugs. Thus, the aims of 
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this investigation were I) pharmacological profiling of novel Cat S inhibitors in 
vitro and in vivo related to transplant immune responses, and II) investigation of 
the possibility of Cat S inhibitors as a preventive drug for ABMR development in 
solid organ transplantation. To discuss the above, I examined two novel Cat S 
inhibitors selected from hundreds of newly synthesized Cat S inhibitors by in vitro 
and in vivo screening assays. 
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Figure 1. Allorecognition pathways in transplantation 
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Chapter I: Pharmacological profiling of 
the novel Cat S inhibitors, AS2761325 and AS2863995 
  
1. Introduction  
Cat S is a cysteine protease of the papain family inside lysosomal/endosomal 
compartments of antigen-presenting cells, such as B cells, macrophages, and 
dendritic cells (Nakagawa and Rudensky, 1999). Antigens internalized into antigen 
presenting cells are transported to the lysosomal/endosomal compartment, digested 
into peptide fragments, and loaded onto MHC class II for presentation to CD4 
positive T cells in the secondary lymphoid organs (Thery and Amigorena, 2001). 
This process depends on the action of proteases in the lysosomal/endosomal 
compartments composed of cysteine proteases (cathepsins B, F, H, L, S and Z), 
aspartate proteases (cathepsins D and E) and serine proteases (cathepsins A and G) 
(Kim et al., 2017). While all cathepsins can function in antigen processing and 
many show overlapping expression patterns, Cat S has been shown to be expressed 
primarily in professional antigen presenting cells (APCs) (Shi et al., 1994). In 
addition, it is well known that Cat S plays a key role in MHC class II antigen 
presentation via proteolytic degradation of liP10 to class II-associated invariant 
chain peptide (CLIP) which is the last in a series of proteolytic cleavages of the 
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MHC class II-associated invariant chain (Nakagawa and Rudensky, 1999).  
Deficiency of Cat S shows immuno-deficient phenotypes, including inhibition 
of development of germinal center and suppression of humoral immune response, 
without specific safety concerns (Nakagawa et al., 1999; Shi et al., 1999). In 
addition, lack of Cat S or pharmacological Cat S inhibition showed suppression of 
autoimmunity in many animal models (Irie et al., 2008; Saegusa et al., 2002; Tato 
et al., 2017), and a Cat S inhibitor has been developed as a drug for Sjögren’s 
syndrome, which is associated with activation of B cells such as the production of 
a variety of autoantibodies and polyclonal hypergammaglobulinemia. The potential 
benefits of Cat S inhibitors for organ transplantation, especially ABMR, have not 
been reported; however, the benefits are likely since Cat S inhibition should be able 
to disrupt both cellular and humoral responses involved in graft rejection. 
In this chapter, I investigated the pharmacologic profile of the novel Cat S 
inhibitors AS2761325 and AS2863995 (Fig. 1-1) obtained from a screening 
evaluation system consisting of cell free, cell based assays and animal experiments. 
To investigate whether Cat S inhibitors have the potential to affect indirect 
allorecognition pathway, so-called DSA production pathway, in transplantation, I 
examined the influence of Cat S inhibitors on an allogeneic antigen presenting 
indirect pathway and in vivo T cell dependent antibody production.  
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2. Materials and methods 
2.1 Animals 
Male BALB/c mice were purchased from Charles River Laboratories Japan, 
Inc. (Kanagawa, Japan). Animals were maintained in a temperature- and humidity-
controlled room with a 12-h light-dark cycle. All animal experimental procedures 
were approved by the Institutional Animal Care and Use Committee of Astellas 
Pharma Inc. The Tsukuba Research Center of Astellas Pharma Inc. has been 
awarded Accreditation Status by AAALAC International. 
 
2.2 Reagents  
AS2761325-00 (the free form of AS2761325, 5-(5-{4-[(pyrrolidin-1-
yl)methyl]piperidine-1-carbonyl}pyridin-3-yl)-4-{[(spiro[2.5] octan-6-
yl)methyl]amino}pyrimidine-2-carbonitrile), AS2863995-CL (the hydrochloride 
salt of AS2863995, 9-methyl-6-{4-[2-(piperidin-4-yl) ethoxy]-3-
(trifluoromethyl)phenyl}-9H-purine-2-carbonitrile hydrogen chloride) were 
synthesized at Astellas Pharma Inc. (Tokyo, Japan).  
 
2.3 Cathepsin protease activity 
The reaction mixture contained 50 mM sodium acetate (pH 4.5), 250 mM 
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NaCl, 5 mM dithiothreitol, and each protease. Recombinant human Cat S, Cat K, 
Cat L, and mouse Cat S were purchased from R&D Systems, Inc. (Minneapolis, 
MN, USA), Enzo Life Sciences, Inc. (Farmingdale, NY, USA), R&D Systems, Inc., 
and Invitrogen Corp. (Carlsbad, CA, USA), respectively. The final concentrations 
of each protease used in the reactions were 20, 12.5 and 2 ng/well for human Cat 
S, K, and L, respectively, and 110 ng/well for mouse Cat S. The substrates and their 
final concentrations were 40 μM Z-Val-Val-Arg-AMC (Peptide Institute, Inc., 
Osaka, Japan), 10 μM Z-Phe-Arg-AMC (Enzo Life Sciences), and 20 μM Z-Leu-
Arg-AMC (R&D systems) for human Cat S, K, and L, respectively, and 20 μM Z-
Val-Val-Arg-AMC for mouse Cat S. AS2761325 and AS2863995 were dissolved 
in dimethyl sulfoxide (DMSO) and mixed with the reaction mixture in a 96-well 
plate (final DMSO concentration, 0.1%). The reaction was initiated by adding the 
substrate, and the fluorescence intensity was measured for 10 min. Protease activity 
was calculated from the fluorescence intensity at 5–10 min, at whichever time the 
reaction curve was linear. 
 
2.4 Protease and kinase panel assay 
Using 1 μM AS2863995, 20 human protease assays (Cat H, Cat V, Cat X/Z/P, 
Cat D, Cat E, Cat G, Caspase 3, Caspase 4, ACE, MMP-1, MMP-9, Pepsin, Renin, 
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Thrombin, Tissue plasminogen activator, DPP-4, Complement component C2, 
Trypsin, u-Plasminogen activator/Urokinase, and 20S Proteasome) and 9 human 
kinase assays (BTK, FGFR1, LCK, TRKA, CDK2/CycA2, IKKβ, IRAK4, p70S6K, 
ROCK1) were performed at Genscript USA Inc. (Piscataway, NJ, USA) and Carna 
Biosciences Inc. (Kobe, Japan), respectively, using their standard protocols. 
 
2.5 MHC class II expression assay in B cells 
Splenocytes from C57BL/6 mice were suspended in RPMI1640 (Sigma, St. 
Louis, MO, USA) supplemented with 10% fetal bovine serum, 50 IU/ml penicillin, 
50 µg/ml streptomycin, and 50 µM 2-mercaptoethanol. Assays were performed in 
96-well round bottom tissue culture plates, with each well containing 1.0 × 105 
splenocytes. Mouse splenocytes were cultured with 2 µg/ml lipopolysaccharide 
(LPS) (Sigma) and AS2761325 or AS2863995 at designated concentrations (final 
DMSO concentration, 0.1%). After incubating for 48 h at 37°C in a humidified 
atmosphere of 5% CO2 and 95% air, cells were washed with 2% fetal bovine serum 
containing CellWASH (BD Biosciences, San Diego, CA, USA) and stained with 
fluorescein isothiocyanate (FITC)-conjugated anti-B220 antibody (BD 
Biosciences) and biotin-conjugated anti-mouse YAe (Invitrogen) followed by 
phycoerythrin (PE)-conjugated streptavidin (BD Biosciences). The fluorescence 
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intensity of PE on B220-positive splenic B cells was measured using the Guava® 
EasyCyte™ Plus Flow Cytometry System and analyzed with Guava Express Pro 
Software (Merck KGaA, Darmstadt, Germany). 
 
2.6 OVA-induced antibody production in mice 
Male BALB/c mice were intraperitoneally injected with antigen-adjuvant 
emulsions containing 100 μg of OVA (Sigma) and 100 μl of complete Freund’s 
adjuvant (Difco Laboratories Inc., Detroit, MI, USA) on day 0, and containing 50 
μg of OVA and 100 μl of incomplete Freund’s adjuvant (Difco Laboratories) on 
day 7. AS2761325 was suspended in 0.5% methylcellulose (MC) solution and 
AS2863995 was dissolved in distilled water containing propylene glycol (PG), 
HCO-40, Tween 80 and hydrochloric acid (PG solvent). Beginning on the day of 
immunization, AS2761325 or AS2863995 were orally administered once daily 
(q.d.), and mice administered 0.5% MC solution or PG solvent were used as the 
respective controls. On day 14 after OVA immunization, mice were bled and 
plasma anti-OVA antibody (IgG) levels were determined by enzyme-linked 
immunosorbent assay. OVA was immobilized in a 96-well immuno plate and 
plasma was added to the wells. After incubation at room temperature, horseradish 
peroxidase-conjugated anti-mouse IgG (Invitrogen) was added to each well, 
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followed by a peroxidase substrate (TMB microwell peroxidase substrate system, 
KPL Inc., Gaithersburg, MD, USA). The peroxidase reaction was stopped by 
adding 1 M sulfuric acid, and the absorbance was read at 450 nm. The amount of 
anti-OVA IgG was calculated using a curve generated from OVA-immunized 
standard plasma. 
 
2.7 Statistical analysis  
All in vitro experiments were performed in duplicate. The IC50 values for 
cathepsin proteases and the cell activation assay were calculated using linear 
regression analysis. OVA-induced antibody levels were expressed as mean ± 
standard error of the mean (S.E.M.), and significant differences between control 
and treatment groups were determined using Dunnett’s multiple comparisons test. 
Statistical analysis was performed using Prism 7 (GraphPad Software Inc., La Jolla, 
CA, USA), and P-values less than 0.05 were considered statistically significant. 
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3. Results 
3.1 In vitro Cathepsin protease activity of AS2761325 and AS2863995 
Two novel and potential Cat S inhibitors, AS2761325 and AS2863995 were 
obtained from the optimization based on structure-activity-relation analysis (Fig. 
1-1). AS2761325 inhibited Cat S protease activity in a concentration-dependent 
manner with an IC50 value of 26 nM for human Cat (hCat) S and 37 nM for mouse 
Cat (mCat) S. Under the same assay conditions, AS2863995 exhibited a more 
potent IC50 value of 1.7 nM for hCat S and 0.92 nM for mCat S. Both compounds 
exhibited the most potent inhibitory activity against hCat S compared to hCat L and 
hCat K. The selectivity of these compounds for hCat S over hCat L and hCat K is 
shown in the Table 1-1. These results indicate that AS2761325 and AS2863995 are 
effective Cat S inhibitors. 
 
3.2 Protease and kinase panel assay for AS2863995 
AS2863995 showed more potent inhibitory activity for hCat S, but slightly 
lower selectivity for hCat L and hCat K compared to AS2761325. Therefore, 
AS2863995 was examined in 20 protease panel assays and 9 kinase panel assays. 
AS2863995 did not show inhibitory activity over 50% at 1 μM against any of the 
tested proteases and kinases (Table 1-2). These results suggested that AS2863995 
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has more than 500 times’ greater selectivity against 20 other proteases and 9 kinases. 
 
3.3 MHC class II expression assay in B cells 
Next, I investigated the cellular potency and efficacy of Cat S inhibitors on 
antigen presentation using the YAe antibody, which specifically recognizes the 
alpha-chain of I-E MHC class II molecules (Ea52–68 peptide) bound to MHC class 
II I-Ab, to examine its effects on antigen presentation suggestive of the indirect 
allorecognition pathway. Both AS2761325 and AS2863995 completely suppressed 
the LPS-induced upregulation of this specific MHC class II/peptide complex (I-
Ab+Ea52–68) on the surface of B cells in a concentration-dependent manner, with 
IC50 values of 100 nM and 0.7 nM, respectively (Fig 1-2). These results suggest 
that AS2761325 and AS2863995 can inhibit the indirect allorecognition pathway. 
 
3.4 In vivo antibody production 
Cat S is required for germinal center development and T cell-dependent 
antibody production (Shi et al., 1999). I therefore investigated the in vivo efficacy 
of the two Cat S inhibitors AS2761325 and AS2863995 on OVA-induced IgG 
production, a T cell-dependent antibody production, in mice. Plasma anti-OVA IgG 
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levels in BALB/c mice were evaluated on day 14 after OVA immunization. Both 
AS2761325 and AS2863995 significantly suppressed the production of anti-OVA 
antibodies compared to control, with inhibition rates of 87% at 100 mg/kg 
AS2761325 and 78% at 3 mg/kg AS2863995 (Fig. 1-3). These results suggest that 
Cat S inhibitors suppress T cell-dependent antibody production. 
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4. Discussion 
Two novel Cat S inhibitors with distinct structures and different potencies 
were used to precisely elucidate the benefits of Cat S inhibition in organ 
transplantation. AS2761325 has an IC50 of 26nM for hCat S, and more than 10 
times selectivity for hCat S over hCat L and hCat K subtypes. AS2863995 showed 
more potent IC50 value of 1.7 nM, and slightly lower selectivity over hCat L and 
hCat K subtypes compared to AS2761325, but more than 500 times selectivity over 
other 20 proteases and 9 kinases. 
In the cell-based assay system, I used the monoclonal antibody, YAe. While 
Cat S plays a critical role in the late stages of invariant chain (Ii) degradation in 
antigen presenting cells, the absence of Cat S or mice long-term treated with Cat S 
inhibitor reportedly do not reduce the expression of MHC class II on APCs (Kim 
et al., 2017; Shi et al., 1999). Furthermore, treatment with Cat S inhibitors make 
the T cell receptor (TCR) repertoire of TFH cells less diverse, suggesting that Cat S 
inhibition impacts selective antigens and alters the pool of peptides presented to 
MHC class II in vivo (Kim et al., 2017). The monoclonal antibody YAe specifically 
recognizes a complex comprising a 52–68 fragment of the alpha-chain of I-E MHC 
class II molecules (Ea52–68 peptide) bound to I-Ab MHC class II molecules (Viret 
and Janeway, 2000). It is reported that C57BL/6 splenocytes (MHC class II; I-Ab) 
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were YAe negative while LPS blasts from these spleens were YAe positive (Viret 
and Janeway, 2000). Furthermore, we empirically found that LPS blasts from Cat 
S null C57BL/6 splenocytes were YAe negative (data not shown), suggesting a 
critical role for Cat S in antigen presentation in the indirect allorecognition pathway. 
In fact, Cat S inhibitors AS2761325 and AS2863995 completely suppressed the 
LPS induced upregulation of specific peptide and MHC class II complex expressed 
on B cells in a concentration-dependent manner. This result suggests that Cat S 
inhibitors can affect the donor HLA allogeneic antigen presenting pathway in the 
indirect allorecognition pathway. 
With regard to the Cat S-independent pathway, it is known that epitopes which 
are made available in less acidic and proteolytic environments are bound by 
recycled MHC class II from the cell surface to early endocytic vesicles (Griffin et 
al., 1997; Pinet et al., 1995). This pathway does not require newly synthesized 
MHC class II and is independent of the invariant chain function. The common 
property of such epitopes is that the parent antigens are relatively structurally 
unconstrained, and influenza virus hemagglutinin has been reported as one of 
example (Sinnathamby and Eisenlohr, 2003). Since the Cat S inhibitor does not 
affect the antigen presentation pathway with this recycled MHC class II, the 
immune response to such antigen is thought to be maintained under Cat S inhibition 
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therapy.  
Furthermore, the immune response against T independent (TI) antigen is also 
considered a Cat S-independent response. Antigens that have a repeating structure 
and are hardly metabolized, such as bacterial product polysaccharide, are known as 
TI antigens, and most of the bacterial, viral and fungal pathogens have surface 
antigens with TI properties (Mond et al., 1995). The most commonly released 
antibody isotype in this type of immune response is low-affinity IgM, but 
considering that T cell-independent antibody production against antigens 
contributes most to defense against infection, this response is thought to be the most 
important for host defense (Alugupalli et al., 2004; TAKAHISHI, 2007). Since TI 
antigens induce antibody production without T cell help, and Cat S deficiency 
results in the lack of interaction between T and APC in the germinal center and T 
cell-dependent antibody production (Shi et al., 1999), Cat S inhibitors appear not 
to affect the immune response to this type of bacterial product. In fact, the Cat S 
inhibitors dose-dependently suppressed T cell-dependent antibody production in 
the OVA-induced antibody production model (Fig. 1-3), but in contrast, lack of Cat 
S or pharmacological Cat S inhibition is reported not to affect IgM production (Shi 
et al., 1999; Tato et al., 2017). 
In the case of solid organ transplantation, DSA production causing ABMR is 
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known to be critically dependent on CD4+ T cells (Lovegrove et al., 2001). 
Although the range that Cat S affects is thought to be limited to the antigen 
presentation pathway by newly synthesized MHC class II molecules, the Cat S 
inhibitors completely inhibited the upregulation of homologous peptide of 
allogeneic antigen in the mature state and suppressed T cell-dependent antibody 
production, suggesting that Cat S inhibitors affect the indirect allorecognition 
pathway, the DSA production pathway, without impairing the extensive humoral 
immune responses.  
In summary, the current study, even with its limitations, demonstrated that 
AS2761325 and AS2863995 are potent, selective, orally bioavailable inhibitors of 
Cat S. They suppressed the upregulation of specific allogeneic antigens 
presentation by MHC class II and in vivo T cell-dependent antibody production. 
The allogeneic antigen presenting pathway was examined using the monoclonal 
antibody YAe which specifically recognizes allogeneic Ea52–68 peptide bound 
MHC class II, but this is one example for the alloantigen presenting pathway. Also, 
this is only the result in an in vitro assay system. Further studies are needed to find 
out if CatS inhibitors are preferred for solid organ transplantation, especially 
ABMR prevention. 
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5. Tables 
 
Table 1-1. Inhibitory activity of AS2761325 and AS2863995 on cathepsins 
(Cat). 
IC50 (nM) Human Cat S Human Cat L Human Cat K Mouse Cat S 
AS2761325 26 530 (20) 980 (38) 37 
AS2863995 1.7 10 (6.1) 15 (9.2) 0.92 
The IC50 value for each protease was calculated using linear regression analysis 
and the numbers in parentheses indicate the selectivity of inhibitory action as the 
ratio of the activity against human Cat S. 
 
  
30 
 
Table 1-2. Inhibitory activity of AS2863995 on various human protease and 
kinase. 
 AS2863995  
1 μM <Positive Control> 
Protease % inhibition compound concentration % inhibition 
Cathepsin H 7.9 E-64 10 μM 74.4 
Cathepsin V 48.9 E-64 10 μM 74.4 
Cathepsin X/Z/P 40.4 Leupeptin 10 μM 95.8 
Cathepsin D 0.1 Pepstain A 1 μM 100.0 
Cathepsin E -12.0 Pepstain A 1 μM 105.1 
Cathepsin G -4.0 Chymostatin 0.33 mM 96.1 
Caspase 3 10.1 Ac-DEVD-CHO 1 μM 89.6 
Caspase 4 1.7 Ac-DEVD-CHO 100 μM 88.1 
ACE 7.8 Captopril 10 μM 103.7 
MMP-1 11.3 GM6001 1 μM 99.8 
MMP-9 17.4 GM6001 1 μM 100.3 
Pepsin 16.1 Pepstain A 1 μM 99.8 
Renin -12.4 Ac-HPFV-(Sta)-LF-NH2 1 μM 98.3 
Thrombin -12.4 Gabexate 10 μM 85.7 
Tissue plasminogen 
activator 14.0 PPACK 10 μM 94.4 
DPP-4 2.5 KR-62436 100 μM 99.1 
Complement 
component C2 9.4 * * * 
Trypsin -5.3 Leupeptin 10 μM 96.0 
u-Plasminogen 
activator/Urokinase 7.4 PPACK 100 μM 98.0 
20S Proteasome -9.5 Epoxomicin 10 μM 100.6 
 Note: * Commercial reference compound was not available 
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 AS2863995  
1 μM <Positive Control> 
Kinase % inhibition compound concentration % inhibition 
BTK 10.3  Staurosporine 10 μM 103.7 
FGFR1 -5.3  Staurosporine 10 μM 101.8 
LCK -0.8  Staurosporine 10 μM 103.3 
TRKA -2.8  Staurosporine 10 μM 102.8 
CDK2/CycA2 -5.7  Staurosporine 10 μM 103.0 
IKKβ 2.1  Staurosporine 10 μM 93.4 
IRAK4 -5.8  Staurosporine 10 μM 101.8 
p70S6K 2.2  Staurosporine 10 μM 102.6 
ROCK1 -1.4  Staurosporine 10 μM 102.3 
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6. Figures 
 
 
AS2761325-00 
 
AS2863995-CL 
Figure 1-1. Chemical structures of AS2761325-00 and AS2863995-CL  
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(A)                                 (B)  
 
 
 
 
 
 
 
 
 
 
AS2761325 IC50; 100 nM   AS2863995 IC50; 0.7 nM 
Figure 1-2. Inhibitory activity of AS2761325 and AS2863995 on major 
histocompatibility complex (MHC) class II expression on mouse B cells. 
Concentration‐dependent inhibition of specific MHC class II expression on B 
cells by Cat S inhibitors. Splenocytes from C57BL/6 mice were cultured with 
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2  µg/ml LPS in the presence of various concentrations of AS2761325 or 
AS2863995 for 48 hours. The expression level of surface YAe which recognized 
specific MHC class II/peptide complex (I-Ab+Ea52–68) on the surface of B cells 
was determined as the geometric mean fluorescence intensity of PE on B220-
positive lymphocytes. The IC50 value was calculated using linear regression 
analysis.  
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Figure 1-3. Effect of Cat S inhibitors on ovalbumin (OVA)-induced antibody 
production in mice.  
Naive Control 10 30 100
0
1
2
3
AS2761325 (mg/kg, p.o.)
**
**
**
65%
71%
87%
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BALB/c mice were intraperitoneally immunized with OVA on day 0 and 7. 
AS2761325 (A) and AS2863995 (B) were administered orally from day 0 to 13. 
Blood samples were collected on day 14 and the ratio of OVA-specific IgG level 
in plasma to that in OVA-immunized standard plasma was calculated. Data 
represent mean±S.E.M. (n=4–11). Differences between control and treated mice 
were compared using one-way analysis of variance followed by the Dunnett’s 
multiple comparisons test. **P<0.01. The dashed lines indicate the lower limit of 
detection. 
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Chapter II: Investigation of the potential of Cat S 
inhibitors as a preventive drug for ABMR development  
in solid organ transplantation 
  
1. Introduction  
The emergence of CNIs dramatically improved graft survival in the acute 
phase. The CNIs tacrolimus and cyclosporin are relatively selective T cell 
inhibitors, so they can effectively suppress TCMR. However, use of 
immunosuppressants is basically faced with side effects, such as the high risk of 
infectious disease, so other classes of immunosuppressants such as anti-metabolite 
MMF and steroids are concomitantly used as maintenance therapy for prevention 
of graft rejection (Srinivas et al., 2007). In this way, TCMR in the acute phase is 
well controlled by current immunosuppressants, but ABMR prevention and 
reversal remain a major medical challenge (Valenzuela and Reed, 2017). A major 
risk factor for antibody-mediated rejection is donor HLA-specific antibody (DSA), 
and insufficient control of ABMR causes a reduction in long-term graft survival 
(Terasaki and Cai, 2008; Wiebe et al., 2015). Therefore, effective anti-ABMR 
therapy is strongly needed to improve overall graft survival and patient quality of 
life.  
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Various treatments have been tested to overcome the issue with ABMR, 
including target therapy of B cells and plasma cells. However, it is difficult to treat 
while retaining a balancing between prevention of ABMR development and 
excessive immunosuppression such as impaired broad humoral immune response. 
From this viewpoint, drugs selective for the DSA production pathway are 
considered desirable, and Cat S inhibitors are thought to have the potential to 
effectively suppress DSA production due to their selective inhibition of the indirect 
allorecognition pathway. While the potential benefits of Cat S inhibitors for organ 
transplantation, especially ABMR, have not been reported, various benefits are 
likely given that Cat S inhibition may prevent both cellular and humoral responses 
involved in graft rejection. 
As shown in Chapter 1, I confirmed that Cat S inhibitors have the potential to 
inhibit indirect allorecognition and DSA production. To clarify the potential of Cat 
S inhibitors in solid organ transplantation, I examined these two Cat S inhibitors in 
a mice heterotopic heart transplantation model. I confirmed the effects of Cat S 
inhibitors on DSA production, which indicates the possibility of ABMR, and on 
graft survival prolongation in the acute phase, which indicates the prevention of 
TCMR. In addition, multivalent combination therapy based on CNIs is a common 
treatment strategy in transplantation, so I examined the effects of Cat S inhibitors 
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under combination therapy with tacrolimus, one of the CNIs. By comparison with 
clinically used conventional immunosuppressants, I explored the potential of Cat S 
inhibitors in solid organ transplantation. 
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2. Materials and methods 
2.1 Animals 
Male C57BL/6 (H-2b) mice and male BALB/c (H-2d) mice were purchased 
from Charles River Laboratories Japan, Inc. (Kanagawa, Japan). Animals were 
maintained in a temperature- and humidity-controlled room with a 12-h light-dark 
cycle. All animal experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Astellas Pharma Inc. The Tsukuba Research 
Center of Astellas Pharma Inc. has been awarded Accreditation Status by AAALAC 
International. 
 
2.2 Reagents  
AS2761325-00 (the free form of AS2761325, 5-(5-{4-[(pyrrolidin-1-
yl)methyl]piperidine-1-carbonyl}pyridin-3-yl)-4-{[(spiro[2.5] octan-6-
yl)methyl]amino}pyrimidine-2-carbonitrile), AS2863995-CL (the hydrochloride 
salt of AS2863995, 9-methyl-6-{4-[2-(piperidin-4-yl) ethoxy]-3-
(trifluoromethyl)phenyl}-9H-purine-2-carbonitrile hydrogen chloride), tacrolimus 
(Prograf® injection or solid dispersion formulation [SDF]), and MMF were 
prepared at Astellas Pharma Inc. (Tokyo, Japan).  
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2.3 Mouse heterotopic heart transplantation 
Male BALB/c and C57BL/6 mice aged 8 weeks were used as cardiac donors 
and recipients, respectively. Heterotopic abdominal cardiac transplantation was 
performed as previously described (Niimi, 2001). 
 
2.3.1 Acute rejection evaluation by graft survival 
AS2761325 was suspended in 0.5% MC solution and AS2863995 was 
dissolved in distilled water containing PG, HCO-40, Tween 80 and hydrochloric 
acid (PG solvent). MMF was suspended in 0.5% MC. These drugs (10 ml/kg q.d.) 
were orally administered to recipients from the day of surgery until 28 days after 
the operation. For tacrolimus, two dosage forms were used depending on the route 
of administration. For subcutaneous administration, tacrolimus (Prograf® injection, 
10 ml/kg q.d.) was diluted in saline and administered from the day of surgery until 
28 days after the operation. For oral administration, tacrolimus (SDF form, 10 
ml/kg q.d.) was suspended in distilled water and administered for 14 days from the 
day of the surgery. Graft survival was monitored by daily palpation of the abdomen 
until 29 days post-transplantation, and graft rejection was defined as cessation of 
palpable cardiac graft beats. Drug administration was continued even after graft 
rejection. 
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2.3.2 Evaluation of DSA production 
DSA levels were analyzed using flow cytometry. C57BL/6 recipient mice 
including those that underwent graft rejection were bled on 28 days after 
transplantation. Plasma from each mouse was incubated with splenocytes (1 × 106 
cells/well) from BALB/c mice for 20 min prior to the addition of PE-conjugated 
anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, 
USA). The mean fluorescence intensities of PE were measured using the Guava® 
EasyCyte™ Plus Flow Cytometry System and analyzed with Guava Express Pro 
Software (Merck KGaA). DSA levels were expressed as the ratio of the mean value 
from the vehicle-treated group in the monotherapy study and as the ratio of the 
mean value from the tacrolimus-alone treatment group in combination therapy with 
tacrolimus. 
 
2.3.3 Analysis of erythroid cell parameters 
Recipient C57BL/6 mice treated with MMF monotherapy were bled on 28 
days after transplantation for analysis of peripheral blood cells. Blood samples were 
collected from the orbital venous plexus using heparinized capillary tubes and 
diluted 3 times with phosphate buffered saline. The numbers of red blood cells 
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(RBC), reticulocyte (RET), and hemoglobin (HGB) in blood samples were 
determined using a Sysmex XT-2000i Automated Hematology Analyzer (Sysmex 
Corporation, Kobe, Japan). For measurement of hematocrit (HCT), the ratio of the 
volume occupied by red blood cells to the volume of whole blood after 
centrifugation of the capillary was calculated using a blood sample for DSA 
analysis. 
 
2.4 Statistical analysis 
Median survival times (MST) of the grafts in the transplant study were 
compared between groups using the log-rank test. Donor-specific antibody levels 
and the number of peripheral blood cells were expressed as mean±S.E.M., and 
significant differences between control and treatment groups were determined 
using Dunnett’s multiple comparisons test. Statistical analysis was performed using 
Prism 7 (GraphPad Software Inc., La Jolla, CA, USA), and P-values less than 0.05 
were considered statistically significant. 
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3. Results 
3.1. Effect of AS2761325 monotherapy on mouse cardiac transplantation 
I assessed the preventive effects of orally administered AS2761325 and 
subcutaneously administered tacrolimus on acute rejection and DSA production in 
a BALB/c-to-C57BL/6 mouse heterotopic cardiac transplantation model. Given 
that the prevalence of acute ABMR and chronic ABMR reportedly increases 1 year 
after detection of DSA in the acute phase (Schinstock et al., 2017), I examined the 
effect of Cat S inhibitors in acute DSA production as a surrogate for predicting 
their effects in acute and chronic ABMR. The MST of engraftment in each control 
group was 6 to 6.5 days. Compared to this, mice treated with tacrolimus at 0.2, 0.3, 
1, and 3 mg/kg showed signiﬁcantly prolonged graft survival, with MSTs of 13, 16, 
>28 and >28 days, respectively. In contrast, 30 and 100 mg/kg AS2761325 
monotherapy did not significantly prolong graft survival (Fig. 2-1 A, B).  
In contrast, under these conditions, AS2761325 significantly inhibited DSA 
production. Specifically, 30 and 100 mg/kg doses inhibited DSA production by 
50% and 69%, respectively, compared to the vehicle-treated group. As tacrolimus 
only showed significant inhibitory effects on DSA production at the doses at which 
significant effects on graft survival were observed, these results indicate that 
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AS2761325 is more effective for inhibiting DSA production than prolonging graft 
survival (Fig. 2-1 C, D).  
 
3.2. Effect of combined AS2761325 therapy on mouse cardiac transplantation 
To further evaluate whether AS2761325 can prolong graft survival, I 
examined the effects of combining AS2761325 with a suboptimal dose of 
tacrolimus in a transplantation model. The dose of tacrolimus was selected such as 
to partially avoid acute TCMR while enabling DSA production in the acute phase. 
AS2761325 was orally administered to recipient mice for 28 days at doses of 10, 
30, and 100 mg/kg, which did not prolong graft survival as a monotherapy (Fig. 2-
1 B). However, in combination with a suboptimal dose of tacrolimus (3.2 mg/kg 
p.o., MST = 13 days), AS2761325 at 30 mg/kg showed a tendency to prolong graft 
survival (MST = 19 days, P = 0.0514) and AS2761325 at 100 mg/kg significantly 
prolonged graft survival (MST > 26 days) (Fig. 2-2 A). These results indicate that 
Cat S inhibitors can prolong graft survival when co-administered with tacrolimus. 
Combination treatment with AS2761325 also inhibited DSA production. 
Compared to the tacrolimus-alone treatment group, AS2761325 at 30 mg/kg and 
100 mg/kg reduced DSA production by 48% and 72%, respectively (Fig. 2-2 B). 
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Therefore, Cat S inhibitors inhibit DSA production in combination therapy as with 
monotherapy.  
 
3.3. Effect of MMF monotherapy on mouse cardiac transplantation 
MMF inhibits T and B lymphocyte proliferation via inosine 5’-
monophosphate dehydrogenase inhibition, which suppresses de novo DSA 
antibody production. However, the dose of MMF is limited due to side effects such 
as gastrointestinal toxicity, leucopenia, anemia, and opportunistic infections. The 
limited dosage of MMF restricts its maximum efficacy (Mele and Halloran, 2000; 
Nakanishi et al., 2012; Vanhove et al., 2013). Therefore, I assessed the preventive 
effects of orally administered MMF on acute rejection and DSA production in this 
BALB/c-to-C57BL/6 mouse heterotopic cardiac transplantation model, and at the 
same time, I examined the influence of MMF on blood cells. Compared to MST of 
6 days in the vehicle treatment group, MMF monotherapy prolonged graft survival 
in a dose-dependent manner, with 50, 100 and 200 mg/kg MMF significantly 
prolonging graft survival with MSTs of 7.5, 18.5 and >28 days, respectively (Fig. 
2-3 A). DSA production was significantly suppressed at 100 and 200 mg/kg MMF, 
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which was at the doses at which significant impact on graft survival was observed, 
as was the case with tacrolimus (Fig. 2-3 B). 
Peripheral blood cell analysis was simultaneously examined using blood 
samples collected on day 28 after transplantation. As a result of the measurement 
of the blood cell parameters, significant decreases in erythroid cells were 
particularly observed from 50 mg/kg treatment for red blood cells, from 100 mg/kg 
treatment for hemoglobin, on 200 mg/kg treatment for reticulocytes, and from 50 
mg/kg treatment for hematocrit (Fig. 2-3 C-F). Anemia is known as one of the dose 
limiting factors for MMF, and from these findings, the tolerable dose of MMF was 
considered 25 to 50 mg/kg in mice. 
 
3.4. Confirmation of the efficacy of Cat S inhibitors using the more potent 
AS2863995 and comparison with MMF 
While concomitant oral administration of multiple drugs is used in clinical 
settings, this can sometimes increase the risk of drug-drug interactions, potentially 
leading to decreased drug concentration in the body. To examine the precise 
maximum effect of Cat S inhibitors with tacrolimus, I further investigated the effect 
of combination treatment comprising AS2863995, a more potent Cat S inhibitor 
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with a different chemical structure to that of AS2761325, and a subcutaneous dose 
of tacrolimus in a mouse cardiac transplantation model. In addition, under 
combination treatment with tacrolimus, the effect of AS2863995 was compared 
with the effect of tolerable doses of MMF in this study. AS2863995 at 3 mg/kg and 
10 mg/kg and MMF at 25 mg/kg and 50 mg/kg were orally administered to 
recipient mice concomitantly with a suboptimal dose of tacrolimus (0.2 mg/kg, s.c., 
q.d.) for 28 days after transplantation. I found that 3 and 10 mg/kg AS2863995 
were comparable to 50 mg/kg MMF in reduction of acute graft rejection. Compared 
to MST of 11.5 days for recipients administered with vehicle plus tacrolimus, 
AS2863995 at 3 and 10 mg/kg plus tacrolimus showed a signiﬁcant prolongation 
of graft survival, with MST of 18.5 days and more than 28 days, respectively. On 
the contrary, MMF 25 mg/kg plus tacrolimus showed no significant prolongation 
of graft survival, and MMF 50 mg/kg plus tacrolimus showed significant 
prolongation with MST of more than 28 days (Fig. 2-4 A).  
Moreover, under these conditions, AS2863995 showed an almost complete 
suppressive effect on DSA production in both 3 and 10 mg/kg treatment, while 50 
mg/kg of MMF showed partial inhibition. The inhibition rate of DSA production 
compared to the tacrolimus single treatment group were 87 % and 92 % in the 3 
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and 10 mg/kg AS2863995 treatment groups, and -5 % and 48 % in the 25 and 50 
mg/kg MMF treatment groups respectively (Fig. 2-4 B).   
These results indicate that AS2863995 showed comparable effects on graft 
survival and inhibition of DSA production at a lower dose than AS2761325, 
potentially due to its higher Cat S inhibition potency. In addition, these data suggest 
that Cat S inhibitors have preventive efficacy against acute rejection, which is 
comparable to 50 mg/kg of MMF, and preferentially suppress DSA production 
more effectively than MMF in organ transplantation.  
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4. Discussion  
In this study, I showed that Cat S inhibitors preferentially suppressed DSA 
production in monotherapy and prolonged graft survival under concomitant 
treatment condition with tacrolimus. In addition, Cat S inhibitor suppressed DSA 
production more effectively than MMF at a dose exhibiting the same extent of graft 
survival prolongation.  
The Cat S inhibitor AS2761325 effectively inhibited DSA production at a 
dose that had no significant effect on graft survival. This compound therefore 
exhibits a unique profile relative to conventional immunosuppressants (Fig. 2-1 
and Fig. 2-3). DSA production, as with conventional protein antigens, is critically 
dependent on CD4+ T cells (Lovegrove et al., 2001). This process is thought to be 
mediated by CD4+ T cells activated via the indirect allorecognition pathway, which 
is involved in the recognition of self-MHC molecule-presenting donor antigens by 
T cells (Bishop et al., 1994; Conlon et al., 2012; Irie, 2013; Lechler et al., 2005). 
Cat S plays an important role in donor antigen loading onto MHC class II molecules 
in lysosomes of APCs and facilitates the presentation of donor antigens to CD4+ 
helper T cells. Indeed, I found that Cat S inhibitors suppressed the upregulation of 
an alloantigen (Ea peptide 52–68) bound to MHC class II I-Ab on the surface of B 
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cells, as described in Chapter 1. The importance of Cat S to antigen presentation in 
dendritic cells and macrophages has also been reported (Nakagawa et al., 1999), 
demonstrating that Cat S inhibitors prevent DSA production after mouse cardiac 
transplantation. In contrast, the weak effect of Cat S inhibitor monotherapy on graft 
survival may be explained by the mechanism of Cat S inhibitors. Cat S inhibitors 
have little effect on the direct antigen allorecognition pathway, which is involved 
in the recognition of intact foreign MHC molecules by T cells, because, in this 
pathway, alloreactive T cells are thought to recognize polymorphic residues on 
allogeneic MHC regardless of the peptide bound to them (Ingulli, 2010). Therefore, 
Cat S inhibitors are thought to effectively suppress DSA production via inhibition 
of the indirect allorecognition pathway.  
The preferential inhibitory effect on DSA production was not observed in 
recipients treated with the conventional immunosuppressants tacrolimus and MMF 
(Fig. 2-1 and Fig. 2-3). MMF inhibits T and B lymphocyte proliferation via inosine 
5’-monophosphate dehydrogenase inhibition and suppresses de novo DSA 
antibody production. However, MMF also inhibits IgM antibody production, which 
is T cell-independent and important in first-line host defense. Further, MMF dose 
is limited due to side effects such as gastrointestinal toxicity, leucopenia, anemia, 
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and opportunistic infections, which restricts maximum efficacy (Mele and Halloran, 
2000; Nakanishi et al., 2012; Vanhove et al., 2013). Therefore, the effect of MMF 
on de novo DSA production in clinical settings may be insufficient. Further, the 
modest inhibition of de novo DSA production may result from high-dose 
immunosuppressive regimens rather than a specific mechanism that reduces de 
novo DSA production (Hourmant et al., 2005; O'Leary et al., 2016). In fact, the 
results of this study showed an increased risk of anemia by administration of MMF 
at the dose at which graft prolongation was observed in monotherapy (Fig. 2-3). 
The CNI agents cyclosporine and tacrolimus, if able to be administered 
without concern for side effects, also suppress humoral immune responses by 
interfering with T helper cell signaling (Heidt et al., 2010). However, current 
maintenance immunotherapies cannot overcome the issues associated with ABMR. 
In fact, a multivariate analysis demonstrated that patients with low CNI trough 
concentrations (tacrolimus <3 ng/ml or cyclosporin <75 ng/ml) are at a highest risk 
of de novo DSA production (O'Leary et al., 2016). These trough levels have been 
observed in some relatively aggressive CNI reduction studies in kidney 
transplantation (Langer et al., 2012), and overall suggest the need to balance the 
benefit of DSA suppression and the risk of side effects. Immunosuppressants that 
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predominantly inhibit DSA production may do so without increasing safety 
concerns compared to nonselective immunosuppressants. Cat S inhibitors do not 
affect IgM production involved in first-line host defense because Cat S inhibitors 
only affect T cell-dependent antibody production responses (Tato et al., 2017). 
While Cat S inhibitors apparently predominantly inhibit the indirect pathway, 
conventional immunosuppressants, including tacrolimus and MMF, show 
relatively broader immunosuppressive effects, including those on CD4+ and CD8+ 
T cells in the direct allorecognition pathway. Particularly at the early stages of 
transplantation, such broad immunosuppressive drugs that act on various types of 
immune cells are preferable from an immunosuppression perspective. Tacrolimus 
and MMF were in fact more effective for graft survival in this mouse 
transplantation study (Fig. 2-1 and 2-3). However, the direct pathway is most 
relevant in the early stages of transplantation due to the lifespan of donor-derived 
antigen presenting cells (Brennan et al., 2009). Meanwhile, the DSA production 
that causes ABMR is thought to occur via the indirect pathway (Bishop et al., 1994; 
Conlon et al., 2012; Irie, 2013; Lechler et al., 2005). Multidrug combination 
therapy is common in transplantation, and an ideal combination regimen might 
therefore be achievable using different profiles of immunosuppressants to 
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overcome the shortcomings while taking advantage of the benefits of each drug. 
The fact that Cat S inhibitors prolonged graft survival when combined with a CNI 
(Fig. 2-2 and 2-4) indicates that the lack of efficacy of Cat S inhibitors at the 
beginning of transplantation can be overcome by combining them with CNIs. In 
the maintenance phase, when indirect allorecognition is dominant, the effective 
suppression of DSA production by Cat S inhibitors due to their selective inhibition 
of the indirect pathway suggests that they have a good profile as ABMR inhibitors 
without increasing safety concerns (Fig. 1).  
In conclusion, I showed the potent immunosuppressive effects of AS2761325 
and AS2863995, novel Cat S inhibitors, in a mouse cardiac transplantation model. 
I found that Cat S inhibitors preferentially suppress DSA production in organ 
transplantation and confirmed that Cat S inhibitors may be promising candidates 
for ABMR prophylaxis drugs.  
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5. Figures 
(A)         (C) 
 
 
 
(B)          (D) 
 
 
 
Figure 2-1. Effect of tacrolimus and AS2761325 monotherapy in mouse 
cardiac transplantation.  
Heterotopic cardiac transplantation was performed using BALB/c and C57BL/6 
mice. Tacrolimus was subcutaneously (A, C) administered while AS2761325 were 
orally administered (B, D) once daily for 28 consecutive days from the day of 
transplantation. (A) Survival of allografts with vehicle or tacrolimus treatment (n 
= 6–7 per group). (B) Survival of allografts with vehicle or AS2761325 treatment 
(n = 3–4 per group). Differences between vehicle and drug-treated mice were 
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compared using the log-rank test. *P<0.05 and **P<0.01. (C) Effect of tacrolimus 
on circulating donor-speciﬁc IgG antibody (DSA-IgG) levels in transplanted mice 
on day 28 after transplantation (n = 2–7 per group). The tacrolimus 3 mg/kg s.c. 
treatment group was evaluated at n=2 because of the loss of samples due to 
technical problems. (D) Effect of AS2761325 on circulating DSA-IgG levels in 
transplanted mice on day 28 after transplantation (n = 3– 4 per group). DSA levels 
were compared with the mean of that in the vehicle-treated group. Data indicate 
mean±S.E.M. Values are presented as ratios of the control. Differences between 
the vehicle and drug-treated groups were compared using the Dunnett’s multiple 
comparisons test. *P<0.05 and **P<0.01. 
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Figure 2-2. Effect of AS2761325 combination therapy with a suboptimal dose 
of tacrolimus in mouse cardiac transplantation.  
Heterotopic cardiac transplantation was performed using BALB/c and C57BL/6 
mice. AS2761325 was orally administered once daily for 28 consecutive days from 
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the day of transplantation, and 3.2 mg/kg of tacrolimus was orally administered 
once daily for 14 consecutive days from the day of transplantation (n = 6–21 per 
group from three independent experiments). (A) Survival of allografts following 
administration of vehicle, tacrolimus or AS2761325 plus tacrolimus. Differences 
between tacrolimus-alone treatment and tacrolimus plus AS2761325 combination 
therapy were compared using the log-rank test. *P<0.05. (B) Effect of AS2761325 
on circulating donor-speciﬁc IgG antibody (DSA-IgG) levels in transplanted mice 
on day 28 after transplantation. DSA levels were compared with the mean of that 
for tacrolimus-alone treatment. Data indicate mean±S.E.M. Values are presented 
as ratios of the control. Differences between tacrolimus-alone treatment and 
tacrolimus plus AS2761325 combination therapy were compared using Dunnett’s 
multiple comparisons test. **P<0.01. 
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Figure 2-3. Effect of mycophenolate mofetil (MMF) in mouse cardiac 
transplantation.   
Heterotopic cardiac transplantation was performed using BALB/c and C57BL/6 
mice. MMF was orally administered once daily for 28 consecutive days from the 
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day of transplantation (n = 6–8 per group). (A) Survival of allografts with vehicle 
or MMF treatment. Differences between vehicle and MMF-treated mice were 
compared using the log-rank test. *P<0.05 and **P<0.01. (B) Effect of MMF on 
circulating donor-speciﬁc IgG antibody (DSA-IgG) levels in transplanted mice on 
day 28 after transplantation. DSA levels were compared with the mean of that in 
the vehicle-treated group. Data indicate mean±S.E.M. Values are presented as 
ratios of the control. Differences between the vehicle and drug-treated groups were 
compared using Dunnett’s multiple comparisons test. **P<0.01. (C) Changes in 
the number of red blood cells (RBC) in transplanted mice peripheral blood sampled 
on day 28 after transplantation. (D) Changes in the number of reticulocytes (RET) 
in transplanted mice peripheral blood sampled on day 28 after transplantation. (E) 
Changes in the concentration of hemoglobin (HGB) in transplanted mice peripheral 
blood sampled on day 28 after transplantation. (F) Changes in hematocrit (HCT) 
levels of transplanted mice peripheral blood sampled on day 28 after 
transplantation. Peripheral blood parameters were compared with the mean of that 
in the vehicle-treated group. Data indicate mean±S.E.M. Differences between the 
vehicle and drug-treated groups were compared using the Dunnett’s multiple 
comparisons test. *P<0.05 and **P<0.01. 
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Figure 2-4. Comparison of AS2863995 with MMF in combination therapy 
with a suboptimal dose of tacrolimus in mouse cardiac transplantation.  
Heterotopic cardiac transplantation was performed using BALB/c and C57BL/6 
mice. MMF and AS2863995 was orally administered and 0.2 mg/kg tacrolimus 
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was subcutaneously administered once daily for 28 consecutive days from the day 
of transplantation (n = 5–9 per group). (A) Survival of allografts following 
tacrolimus and tacrolimus plus MMF or AS2863995 treatment. Differences 
between tacrolimus-alone treatment and tacrolimus plus MMF or AS2863995 
combination therapy were compared using the log-rank test. *P<0.05 and **P<0.01. 
(B) Effect of AS2863995 on circulating donor-speciﬁc IgG antibody (DSA-IgG) 
levels in transplanted mice on day 28 after transplantation. DSA levels were 
compared with the mean of that for tacrolimus-alone treatment. Data indicate 
mean±S.E.M. Values are presented as ratios of the control. Differences between 
tacrolimus-alone treatment and tacrolimus plus MMF or AS2863995 combination 
therapy were compared using Dunnett’s multiple comparisons test. **P<0.01.  
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General Discussion 
I used two novel Cat S inhibitors with distinct structures and different 
potencies to precisely elucidate the benefits of Cat S inhibition in organ 
transplantation. These two compounds inhibited selective MHC class II antigen 
presentation on mouse splenic B cells and suppressed T cell-dependent antibody 
production. In the mouse cardiac transplantation study, the Cat S inhibitors 
prolonged graft survival and prevented de novo DSA production under concomitant 
treatment with tacrolimus. 
Belatacept is one of the drugs expected to be used in immunosuppressive 
maintenance therapy for ABMR prevention (O'Leary et al., 2016). Various 
biological therapies have been trialed in recent years for the prevention of ABMR. 
Most deplete T, B, and plasma cells, and are used as induction therapies, whereas 
belatacept blocks the costimulatory signal between T cells and APCs, and is used 
as maintenance therapy (O'Leary et al., 2016; Valenzuela and Reed, 2017). 
According to recently published data from the BENEFIT and BENEFIT-EXT 
studies, which summarized 7 years of phase 3 trial outcomes, CNI-free belatacept-
based therapies consistently improve the glomerular filtration rate and decrease de 
novo DSA production. However, these therapies increase the incidence of acute T-
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cell mediated rejection episodes 1 year after transplantation and increased the risk 
of post-transplant lymphoproliferative disorder in Epstein Barr virus-seronegative 
recipients (Riella et al., 2016). CD28-B7 costimulatory blockade also preferentially 
prevents alloantibody production in mice treated with cytotoxic T lymphocyte-
associated protein-4-Ig (Oh et al., 2016; Young et al., 2016). Cat S inhibitors 
suppress interactions between T cells and APCs via MHC class II/TCR interaction 
(signal 1) and are thought to have a mode of action most similar to CD28-B7 (signal 
2) blockade among the clinically used immunosuppressants in transplantation. 
Several pathways other than the CD28-B7 pathway are known to mediate 
costimulation between naïve/memory T cells and APCs in transplantation (Oshima 
et al., 2016; Pilat et al., 2011). Additionally, many studies in animal models have 
demonstrated that donor-reactive memory T cells can induce allograft responses 
despite blocking the essential costimulatory pathways (Adams et al., 2003; 
Onodera et al., 1997), and that CD4+ memory T cells aid DSA production to induce 
alloantibody-mediated graft injury (Benichou et al., 2017). Given that activation of 
memory CD4+ T cells requires antigen recognition (McKinstry et al., 2010), Cat S 
inhibitors may effectively inhibit recurrent DSA production and may therefore be 
more effective than costimulatory blockade. The effect of Cat S inhibitors on 
memory T cells warrants further investigation. 
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Although Cat S-deficient mice are healthy and normal in most respects 
(Nakagawa et al., 1999), recent evidence of roles for Cat S outside of MHC class 
II processing in various pathological conditions such as pain, colitis, and cancer 
has revived interest in Cat S as a therapeutic target (Wilkinson et al., 2015). Cat S 
reportedly has an additional biological function in vascular endothelial cells via 
protease-activated receptor (PAR)-2 and this pathway contributes to microvascular 
complications in diabetic mice (Kumar Vr et al., 2016). Cat S inhibitors also 
suppress immune complex-induced vasculopathy via PAR-2 blockade in a systemic 
lupus erythematosus mouse model (Tato et al., 2017). Vasculopathy induced by 
immune complex is one of the manifestations associated with ABMR (Valenzuela 
and Reed, 2017). Although further studies are needed to determine the contribution 
of PAR-2 to transplant vasculopathy, these non-immunological properties of Cat S 
inhibitors further justify their effectiveness as ABMR suppressants.  
The growing interest in Cat S as a therapeutic target has also prompted the 
development of new selective inhibitors and detection techniques for 
pharmacodynamics markers to predict responses to these treatments. Despite 
unsuccessful historical attempts, in recent years, a number of selective Cat S 
inhibitors have been developed, and biomarker detection technologies have 
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revealed the dose-dependent target engagement of Cat S inhibitors in clinical 
studies (Payne et al., 2014; Theron et al., 2017). From this background, clinical 
investigations of Cat S inhibitors are expected to yield useful findings in the 
transplantation field. To determine the clinical application of Cat S inhibitors in 
transplantation, future studies should evaluate these compounds in primates. 
While the present findings in this research provide the potential of Cat S 
inhibitors to the unmet need of current therapies for solid organ transplantation, 
further studies on these aspects as mentioned above will allow a broader 
characterization of the therapeutic potential of Cat S inhibitors. I hope that this 
research and future studies open the way of transplant patients. 
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Conclusion 
As summary of this dissertation, I summarize important findings in current 
investigation as follows; I) AS2761325 and AS2863995 are potent and selective 
Cat S inhibitors, II) Cat S has important roles in alloantigen loading onto MHC 
class II molecules, III) Cat S selective inhibitors effectively prevent T cell-
dependent antibody production, and IV) Cat S selective inhibitors preferentially 
suppress DSA production in organ transplantation by selectively inhibiting indirect 
allorecognition pathway. Taken together, these findings show that Cat S selective 
inhibitors may be promising candidates for ABMR prophylaxis drugs.  
I am confident that this first attempt at the assessment of Cat S inhibitors in 
the transplantation field showed the possibility of more specific inhibition of DSA 
production, clarified the site of action in ABMR, and contributed to advancing our 
understanding of the disease mechanism. I strongly hope that my research will lead 
to the development of new specific drugs that will dramatically improve the 
transplantation society.  
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